The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
OrbiMed Advisors LLC and related funds filed Amendment No. 3 to update their stake in Q32 Bio Inc. following a private placement. The reporting persons now may be deemed to beneficially own 4,127,987 common shares, representing 17.4% of the company. Based on 23,681,415 shares outstanding, OrbiMed Private Investments VII, LP holds 3,502,987 shares, or 14.8%, and OrbiMed Genesis Master Fund, L.P. holds 625,000 shares, or 2.6%. These positions reflect a May 2026 PIPE in which OPI VII bought 1,250,000 shares and Genesis bought 625,000 shares at $8.00 per share. The filing also details registration rights agreements providing for resale registration of shares from both the earlier merger financing and the recent private placement.
Q32 Bio Inc. received new investment from several Atlas Venture funds, which filed Amendment No. 1 to their Schedule 13D to update ownership details. Atlas Venture Opportunity Fund III bought 625,000 shares of common stock at $8.00 per share in a 2026 private placement (PIPE), for a total of $5 million.
After this transaction, the Atlas reporting entities collectively beneficially own 2,717,106 shares of Q32 Bio common stock, or about 11.5% of the 23,681,415 shares outstanding as of May 28, 2026. The PIPE added 6,725,000 shares to the prior 16,956,415 shares outstanding. Q32 Bio also agreed to a registration rights agreement, requiring it to file and have declared effective a registration statement covering the resale of PIPE shares and shares issuable from pre-funded warrants within a set timeframe.
Q32 Bio Inc. entered a securities purchase agreement with institutional and accredited investors for a private placement of 6,725,000 common shares and pre-funded warrants to purchase 150,000 shares. The shares are priced at $8.00 each and the warrants at $7.9999 with a nominal $0.0001 exercise price.
The pre-funded warrants are immediately exercisable and subject to a 9.99% beneficial ownership cap, adjustable up to 19.99% with 61 days’ notice. Q32 Bio expects aggregate gross proceeds of approximately $55 million, to be used with existing cash to advance clinical trials for bempikibart and for working capital and general corporate purposes. Closing is expected on May 28, 2026, and the company has agreed to file a resale registration statement for the shares and warrant shares.
Q32 Bio Inc. ownership update: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared voting and dispositive power over 958,768 shares of Common Stock, representing 5.7% of the class as of the close of business on May 14, 2026. The cover page footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 0 shares. The filing attributes voting and investment power to Point72 Associates under an investment management agreement; Point72 Capital Advisors Inc. is the general partner and Mr. Cohen controls both entities.
Sirenia Capital Management and Alex Silverstein report beneficial ownership of Common Stock in Q32 Bio Inc. The filing states a reported position of 2,057,308 shares, representing 9.9% of the class on a fully‑exercised basis subject to a 9.99% blocker. The percentage calculation uses 14,629,463 shares outstanding as of March 1, 2026. The filing also discloses 1,025,654 shares issuable upon exercise of reported warrants held by the Sirenia Fund and notes the blocker limits exercise to prevent ownership above 9.99%.
Q32 Bio Inc. received an updated Schedule 13D/A from OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC reporting their current stake in the company. Through OrbiMed Private Investments VII, LP, they beneficially own 2,252,987 shares of common stock, representing about 13.3% of Q32 Bio’s 16,956,415 shares outstanding as referenced in a recent quarterly report. The filing notes this percentage fell by more than 1% because the total shares outstanding increased, not because OrbiMed sold shares. OrbiMed states it may buy more or sell shares over time depending on Q32 Bio’s performance and market conditions. An OrbiMed employee, Diyong Xu, sits on Q32 Bio’s board, and any equity awards he receives as a director are assigned back to OrbiMed’s fund. The filing also highlights a registration rights agreement requiring Q32 Bio to file a shelf registration to allow resale of certain shares issued in connection with a prior financing and merger.
Opaleye Management Inc., Opaleye, L.P. and James Silverman filed an amended Schedule 13G reporting shared beneficial ownership of 1,256,228 shares of Q32 Bio Inc. Common Stock, representing 8.59% of the class. The filing states the interest is based on 14,629,463 shares outstanding as of March 1, 2026, as reported in Q32 Bio's Form 10-K. The statement explains the Fund directly holds the shares, the Adviser serves as investment adviser, and Mr. Silverman controls the Adviser; the joint filing agreement is included.
Q32 Bio Inc. is a clinical-stage biotech focused on bempikibart for alopecia areata and other autoimmune diseases. For the quarter ended March 31, 2026, it reported a net loss of $7.6 million, improved from $11.0 million a year earlier, as research and development expenses fell to $3.2 million and general and administrative costs to $4.5 million.
Cash and cash equivalents were $50.8 million, with total cash, cash equivalents, restricted cash and restricted cash equivalents of $51.4 million. Management believes this is sufficient to fund operations for at least one year from the financial statement issuance date, though the company expects continued operating losses and will likely need additional capital over time.
During the quarter, Q32 completed a registered direct offering, issuing 1,666,679 shares of common stock and pre-funded warrants for net proceeds of $10.4 million. It also put in place an at-the-market equity program allowing sales of up to $14.2 million of common stock under an effective shelf registration, with no ATM shares sold by March 31, 2026. After quarter-end, the company sold 2,326,952 shares under the ATM for $13.8 million in net proceeds and expanded the ATM capacity by filing a prospectus supplement for up to an additional $75 million.
Q32 Bio Inc. reported a smaller net loss for the quarter ended March 31, 2026 while advancing its lead alopecia areata program. Net loss was $7.6 million, or $0.54 per share, compared with $11.0 million, or $0.90 per share, a year earlier, driven by lower research and development and general and administrative expenses.
Cash and cash equivalents were $50.8 million as of March 31, 2026. Together with a completed $10.5 million registered direct offering, $14.2 million from the ATM program and guaranteed near-term milestone payments, the company expects its financial runway to extend into the first half of 2028. Q32 Bio expects 36-week topline data from the Part B Phase 2a SIGNAL-AA trial of bempikibart in mid-2026 and has begun dosing patients in an open-label extension.